Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 3/20 | 0.46 |
| ▸ | SDHB | P21912 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445065 | 0.83 | SDHB (0.54) | CMA1GSK3AGSK3BMAPTTP53 | |
| SCHEMBL8276905 | 0.83 | CMA1 (0.53) | CMA1GSK3AGSK3BMAPTTP53 | |
| SCHEMBL2458827 | 0.81 | CMA1 (0.51) | CMA1GSK3AGSK3BMAPTTP53 | |
| SCHEMBL32665056 | 0.80 | SDHB (0.38) | MAPTLMNASDHBKDM4EALDH1A1 | |
| SCHEMBL2458693 | 0.79 | ALDH1A1 (0.51) | CMA1GSK3AGSK3BMAPTTP53 | |
| SCHEMBL32665579 | 0.79 | BRD4 (0.40) | MAPTLMNAAPPALDH1A1SMN1; SMN2 | |
| SCHEMBL17420665 | 0.78 | BRD4 (0.53) | CMA1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6116487 | 0.78 | ALDH1A1 (0.65) | CMA1MAPTTP53LMNASDHB | |
| SCHEMBL5448579 | 0.78 | MEN1 (0.56) | CMA1GSK3AGSK3BMAPTTP53 | |
| SCHEMBL5437535 | 0.78 | NPBWR1 (0.52) | CMA1GSK3AGSK3BMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | CMA1 3621/4885GSK3A 4013/4885GSK3B 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.